Mandrake Bio funding, investors and company details

Mandrake Bio is an emerging Artificial Intelligence (AI) - Deeptech startup from Bengaluru, working in the space of Biotech startup developing AI-powered gene-editing enzymes from the ground up. Founded by Tanay Lohia, Kutubuddin Molla.

Company: Mandrake Bioworks Pvt. Ltd.
Sector: Artificial Intelligence (AI) - Deeptech
Location: Bengaluru
Founders: Tanay Lohia, Kutubuddin Molla

Company overview

Mandrake Bio is a biotech startup developing AI-powered gene-editing enzymes from the ground up. Unlike conventional gene-editing approaches that modify naturally occurring proteins such as CRISPR-Cas9, the company uses generative AI, structural biology, and biophysics to design entirely new, compact, and highly programmable gene-editing enzymes computationally — then validates them through wet lab testing. Its target markets are agriculture and human therapeutics, with an initial focus on developing precision gene-editing tools for crop improvement and genetic medicine. The company intends to license its proprietary enzyme designs to established seed and pharmaceutical firms. It has raised pre-seed funding co-led by prominent early-stage investors.

Funding rounds

Latest round (Pre-Seed): ₹16.00 Cr. ($ 1.67 Mn), 2026-07-17. Investors: Antler India, Spectrum Impact, DEVC, Sanjiv Rangrass (Capria), Activate VC, Vijay Chandru, Paras Chopra, Vatsal Dusad